Gut Microbiome and Longevity: Tests, Interpretation and What Works

The dysbiosis stool test is one of the most ordered and least informative tests in medicine. It cultures only about 30% of the species living in the gut — the rest die on contact with oxygen or simply refuse to grow in lab conditions. Yet the gut microbiome directly influences immunity, inflammation, metabolism and cognitive function — making it a core longevity variable.

Meaningful microbiome analysis requires a different technology: 16S rRNA sequencing or metagenomic testing provides real composition data. Here is what the tests actually show, what they cannot, and what the evidence says about improving microbiota.

Why Standard Dysbiosis Tests Are Outdated

The dysbiosis diagnosis as a stand-alone concept is not recognised by international medicine — it does not appear in ICD-10 or ICD-11. This does not mean microbiome imbalance is not real. It means that standard culture-based stool analysis cannot reliably detect it.

The core problem: lab cultures capture roughly 30% of intestinal species. Obligate anaerobes — most of the gut's population — die on oxygen exposure or fail to grow on standard media. Interpreting such a test is like judging a library by reading one shelf.

A compounding issue: reference ranges for "lactobacilli" and "bifidobacteria" in these tests were derived from Soviet-era studies of the 1970s. Healthy microbiome composition varies tenfold between individuals, and no single correct composition exists.

Modern Microbiome Testing: Metagenomic and 16S rRNA Sequencing

Two molecular approaches deliver genuinely useful microbiome data:

16S rRNA sequencing: all bacteria carry the 16S ribosomal RNA gene, whose sequence is unique to each genus and species. Analysing stool DNA identifies virtually every bacterial species present — including anaerobes that never grow in culture. This is the current research gold standard.

Metagenomic sequencing: the entire DNA content of the sample is sequenced — bacteria, viruses, fungi and archaea alike. More expensive but the most complete picture available. Used primarily in research settings.

Both methods report: gut composition, microbial diversity (alpha-diversity), and abundance of key species (Akkermansia muciniphila, Faecalibacterium prausnitzii, Bifidobacterium).

What a Microbiome Analysis Can Tell You: Interpretation of Results

Interpretation of modern microbiome test outputs falls into two categories: robust signals and speculative findings. Clinically actionable outputs:

• Alpha-diversity (total species count): higher is better — a robust marker of microbiome health and biological age
• Akkermansia muciniphila: a keystone species maintaining intestinal mucosal integrity; low levels correlate with insulin resistance and elevated inflammation
• Firmicutes/Bacteroidetes ratio: Firmicutes dominance correlates with obesity, though research results are mixed
• Short-chain fatty acids (SCFA — butyrate, propionate, acetate): fermentation products of dietary fibre; markers of a well-functioning microbiome

What the analysis cannot tell you: a single "correct" composition for your specific case, or the direct cause of specific symptoms without clinical context.

The Microbiome, Gut Immunity and Chronic Inflammation

Seventy per cent of the body's immune cells reside in the gut. Breakdown of the mucosal barrier ("leaky gut") allows bacterial lipopolysaccharides (LPS) to enter the bloodstream, triggering systemic inflammation — a central mechanism of biological ageing.

This is how dysbiosis connects to elevated C-reactive protein: hs-CRP above 2 mg/L with no obvious cause frequently points to gut-driven inflammation. The Human Microbiome Project found that individuals with low microbiome diversity had hs-CRP on average 40% higher than those with high diversity.

The same link applies to insulin resistance: Akkermansia muciniphila produces propionate, which improves insulin sensitivity. Three human trials showed that Akkermansia supplementation or prebiotic support reduces HOMA-IR by 15–25%.

Indirect Markers of Intestinal Health in Blood Tests

While metagenomic testing is unavailable or expensive, standard blood tests provide indirect microbiome signals:

hs-CRP (C-reactive protein): below 1 mg/L indirectly indicates the absence of significant gut inflammation. Rising hs-CRP with no obvious cause warrants considering gut dysbiosis.

Ferritin: chronic gut inflammation frequently elevates ferritin. Ferritin above 200 ng/mL in men without other causes is an indirect systemic inflammation marker, potentially gut-driven.

Vitamin D: vitamin D deficiency impairs the gut immune barrier and promotes dysbiosis. The relationship is bidirectional: dysbiosis reduces vitamin D absorption.

Homocysteine: gut bacteria participate in producing and recycling B-vitamins. Dysbiosis impairs folate synthesis, raising homocysteine even without dietary deficiency.

What Actually Improves the Microbiome: Research Evidence

Dietary diversity: the American Gut Project (10,000 participants) showed that people eating more than 30 different plant species per week have significantly greater microbiome diversity than those eating fewer than 10.

Fermented foods: a randomised trial by Wastyk et al. (Cell, 2021) — 10 weeks of a fermented-food-rich diet (kefir, kimchi, sauerkraut) significantly increased microbiome diversity and reduced hs-CRP — more effectively than a high-fibre diet alone.

Prebiotics: inulin, FOS and arabinoxylan feed beneficial bacteria selectively. Targeted support for Bifidobacterium and Faecalibacterium prausnitzii reduces inflammation and supports mucosal barrier function.

Probiotics: effects are strictly strain-specific. Lactobacillus rhamnosus GG for diarrhoea — proven. A generic "probiotic" for everything — does not work. Transient bacteria from a capsule pass through without establishing residence.

When to Get a Microbiome Test

Clinically warranted for: persistent unexplained bloating, diarrhoea or constipation lasting over 3 months, post-antibiotic GI disturbance, elevated hs-CRP with no clear cause, and autoimmune conditions.

Not warranted: the standard culture-based dysbiosis test — it provides no clinically useful information. Replace it with 16S rRNA sequencing if microbiome data is genuinely needed.

Optimal format: 16S rRNA sequencing combined with SCFA analysis. For a complete annual longevity monitoring protocol, see the annual blood test checklist and how to live longer: the evidence base.